Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (13605)
All Articles published online
|
Publishing Process of This Article
|
Sep 28, 2018 (publication date) through Mar 2, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG, De Matteis S, Ercolani G, Valgiusti M, Frassineti GL, Scartozzi M, Casadei Gardini A. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? World J Gastroenterol 2018; 24(36): 4152-4163 [PMID: 30271080 DOI: 10.3748/wjg.v24.i36.4152] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v24/i36/4152.htm |
| Number | Citing Articles |
| 1 |
Fangfang Zhao, Guohe Feng, Junyao Zhu, Zhijun Su, Ruyi Guo, Jiangfu Liu, Huatang Zhang, Yongzhen Zhai. 3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy. Anti-Cancer Drugs 2021; 32(4): 386 doi: 10.1097/CAD.0000000000001032
|
| 2 |
Evgenia Kotsifa, Chrysovalantis Vergadis, Michael Vailas, Nikolaos Machairas, Stylianos Kykalos, Christos Damaskos, Nikolaos Garmpis, Georgios D. Lianos, Dimitrios Schizas. Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?. Journal of Personalized Medicine 2022; 12(3): 436 doi: 10.3390/jpm12030436
|
| 3 |
Gourab Ghosh Roy, Nicholas Geard, Karin Verspoor, Shan He, Inanc Birol. MPVNN: Mutated Pathway Visible Neural Network architecture for interpretable prediction of cancer-specific survival risk. Bioinformatics 2022; 38(22): 5026 doi: 10.1093/bioinformatics/btac636
|
| 4 |
Bao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Guang-Xiao Meng, Jun-Shuai Xue, Cheng-Long Han, Zhao-Ru Dong, Jian-Guo Hong, Zhi-Qiang Chen, Dong-Xu Wang, Tao Li. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis. Expert Review of Gastroenterology & Hepatology 2023; 17(1): 73 doi: 10.1080/17474124.2022.2156859
|
| 5 |
Jessica Elderkin, Najeeb Al Hallak, Asfar S. Azmi, Hussein Aoun, Jeffrey Critchfield, Miguel Tobon, Eliza W. Beal. Hepatocellular Carcinoma: Surveillance, Diagnosis, Evaluation and Management. Cancers 2023; 15(21): 5118 doi: 10.3390/cancers15215118
|
| 6 |
Anil Aysal, Ozgul Sagol. Biomarkers in Carcinoma of Unknown Primary. 2022; : 201 doi: 10.1007/978-3-030-84432-5_8
|
| 7 |
Homood M. As Sobeai, Munirah Alohaydib, Ali R. Alhoshani, Khalid Alhazzani, Mashal M. Almutairi, Tareq Saleh, David A. Gewirtz, Moureq R. Alotiabi. Sorafenib, rapamycin, and venetoclax attenuate doxorubicin-induced senescence and promote apoptosis in HCT116 cells. Saudi Pharmaceutical Journal 2022; 30(1): 91 doi: 10.1016/j.jsps.2021.12.004
|
| 8 |
Howard Lim, Ravi Ramjeesingh, Dave Liu, Vincent C Tam, Jennifer J Knox, Paul B Card, Brandon M Meyers. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review. JNCI: Journal of the National Cancer Institute 2021; 113(2): 123 doi: 10.1093/jnci/djaa119
|
| 9 |
Nia Adeniji, Renumathy Dhanasekaran. Genomic Landscape of HCC. Current Hepatology Reports 2020; 19(4): 448 doi: 10.1007/s11901-020-00553-7
|
| 10 |
Debasis Das, Lingzhi Xie, Dandan Qiao, Jianhe Jia, Jian Hong. Discovery of novel, orally bioavailable phenylacetamide derivatives as multikinase inhibitors and in vivo efficacy study in hepatocellular carcinoma animal models. Bioorganic & Medicinal Chemistry Letters 2024; 113: 129971 doi: 10.1016/j.bmcl.2024.129971
|
| 11 |
Young Youn Cho, Su Jong Yu, Hye Won Lee, Do Young Kim, Wonseok Kang, Yong-Han Paik, Pil Soo Sung, Si Hyun Bae, Su Cheol Park, Young Seok Doh, Kang Mo Kim, Eun Sun Jang, In Hee Kim, Won Kim, Yoon Jun Kim. Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. Journal of Hepatocellular Carcinoma 2021; : 613 doi: 10.2147/JHC.S304439
|
| 12 |
Young Hoon Jung, Yun Ji Lee, Tam Dao, Kyung Hee Jung, Junjie Yu, Ah-Reum Oh, Yelin Jeong, HyunJoon Gi, Young Un Kim, Dongryeol Ryu, Michele Carrer, Utpal B. Pajvani, Sang Bae Lee, Soon-Sun Hong, KyeongJin Kim. KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression. Clinical and Molecular Hepatology 2024; 30(4): 895 doi: 10.3350/cmh.2024.0364
|
| 13 |
Zuzanna Sas, Ewa Cendrowicz, Isabel Weinhäuser, Tomasz P. Rygiel. Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options. International Journal of Molecular Sciences 2022; 23(7): 3778 doi: 10.3390/ijms23073778
|
| 14 |
Jin-Man Zhang, Yao-Yao Jiang, Qun-Fa Huang, Xu-Xiu Lu, Guan-Hai Wang, Chang-Lun Shao, Ming Liu. Brefeldin A delivery nanomicelles in hepatocellular carcinoma therapy: Characterization, cytotoxic evaluation in vitro, and antitumor efficiency in vivo. Pharmacological Research 2021; 172: 105800 doi: 10.1016/j.phrs.2021.105800
|
| 15 |
Nurbubu T. Moldogazieva, Sergey P. Zavadskiy, Susanna S. Sologova, Innokenty M. Mokhosoev, Alexander A. Terentiev. Predictive biomarkers for systemic therapy of hepatocellular carcinoma. Expert Review of Molecular Diagnostics 2021; 21(11): 1147 doi: 10.1080/14737159.2021.1987217
|
| 16 |
Guo-Ying Feng, Yu Cheng, Kai Chen, Zheng-Rong Shi, Antonio Giovanni Solimando. Correlation between Immunohistochemical Markers in Hepatocellular Carcinoma Cells and In Vitro High-Throughput Drug Sensitivity Screening. Canadian Journal of Gastroenterology and Hepatology 2022; 2022: 1 doi: 10.1155/2022/5969716
|
| 17 |
Kehua Zhou, Christos Fountzilas. Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma. Cancers 2019; 11(6): 861 doi: 10.3390/cancers11060861
|
| 18 |
Binyu Qin, Zhili Zeng, Jianliang Xu, Jing Shangwen, Zeng Jie Ye, Shutang Wang, Yanheng Wu, Gongfeng Peng, Qi Wang, Wenyi Gu, Ying Tang. Emodin inhibits invasion and migration of hepatocellular carcinoma cells via regulating autophagy-mediated degradation of snail and β-catenin. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-09684-0
|
| 19 |
Snehal K. Shukla, Mimansa Goyal, Dipti D. Kanabar, Seyoum Ayehunie, Bhavesh Deore, Carlos A. Sanhueza, Aaron Muth, Vivek Gupta. Exploring the enhanced stability and therapeutic efficacy of Sorafenib-Cyclodextrin inclusion complex. Journal of Molecular Liquids 2024; 401: 124701 doi: 10.1016/j.molliq.2024.124701
|
| 20 |
Hui Li. Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Review of Gastroenterology & Hepatology 2021; 15(3): 217 doi: 10.1080/17474124.2021.1842732
|
| 21 |
Satoshi Noda, Shin-ya Morita, Tomohiro Terada. Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring. Biological and Pharmaceutical Bulletin 2022; 45(7): 814 doi: 10.1248/bpb.b21-01098
|
| 22 |
Wendy Wei Gan, Lai Wah Chan, Wenji Li, Tin Wui Wong. Critical clinical gaps in cancer precision nanomedicine development. Journal of Controlled Release 2022; 345: 811 doi: 10.1016/j.jconrel.2022.03.055
|
| 23 |
Eleonora Lai, Giorgio Astara, Pina Ziranu, Andrea Pretta, Marco Migliari, Marco Dubois, Clelia Donisi, Stefano Mariani, Nicole Liscia, Valentino Impera, Mara Persano, Simona Tolu, Francesca Balconi, Giovanna Pinna, Dario Spanu, Annagrazia Pireddu, Giorgio Saba, Silvia Camera, Francesca Musio, Marco Puzzoni, Valeria Pusceddu, Clelia Madeddu, Andrea Casadei Gardini, Mario Scartozzi. Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?. Critical Reviews in Oncology/Hematology 2021; 157: 103167 doi: 10.1016/j.critrevonc.2020.103167
|
| 24 |
Simon Gray, Angela Lamarca, Julien Edeline, Heinz-Josef Klümpen, Richard A. Hubner, Mairéad G. McNamara, Juan W. Valle. Targeted Therapies for Perihilar Cholangiocarcinoma. Cancers 2022; 14(7): 1789 doi: 10.3390/cancers14071789
|
| 25 |
Hiroaki Takaya, Tadashi Namisaki, Naotaka Shimozato, Kosuke Kaji, Mitsuteru Kitade, Kei Moriya, Shinya Sato, Hideto Kawaratani, Takemi Akahane, Masanori Matsumoto, Hitoshi Yoshiji. ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2019; 11(5): 424-435 doi: 10.4251/wjgo.v11.i5.424
|
| 26 |
Mona M. AbouSamra. Liposomal nano-carriers mediated targeting of liver disorders: mechanisms and applications. Journal of Liposome Research 2024; 34(4): 728 doi: 10.1080/08982104.2024.2377085
|
| 27 |
Lucia Cerrito, Maria Elena Ainora, Carolina Mosoni, Raffaele Borriello, Antonio Gasbarrini, Maria Assunta Zocco. Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy. Cancers 2022; 14(19): 4647 doi: 10.3390/cancers14194647
|
| 28 |
Utibe-Abasi S. Udoh, Moumita Banerjee, Pradeep K. Rajan, Juan D. Sanabria, Gary Smith, Mathew Schade, Jacqueline A. Sanabria, Yuto Nakafuku, Komal Sodhi, Sandrine V. Pierre, Joseph I. Shapiro, Juan R. Sanabria. Tumor-Suppressor Role of the α1-Na/K-ATPase Signalosome in NASH Related Hepatocellular Carcinoma. International Journal of Molecular Sciences 2022; 23(13): 7359 doi: 10.3390/ijms23137359
|
| 29 |
Marta Correia de Sousa, Nicolas Calo, Cyril Sobolewski, Monika Gjorgjieva, Sophie Clément, Christine Maeder, Dobrochna Dolicka, Margot Fournier, Laurent Vinet, Xavier Montet, Jean-François Dufour, Bostjan Humar, Francesco Negro, Christine Sempoux, Michelangelo Foti. Mir-21 Suppression Promotes Mouse Hepatocarcinogenesis. Cancers 2021; 13(19): 4983 doi: 10.3390/cancers13194983
|
| 30 |
Nevin Varghese, Amry Majeed, Suraj Nyalakonda, Tina Boortalary, Dina Halegoua-DeMarzio, Hie-Won Hann. Review of Related Factors for Persistent Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Cancers 2024; 16(4): 777 doi: 10.3390/cancers16040777
|
| 31 |
Sheng Li, Lina Wu, Hong Zhang, Xijuan Liu, Zilei Wang, Bin Dong, Guang Cao. GINS1 Induced Sorafenib Resistance by Promoting Cancer Stem Properties in Human Hepatocellular Cancer Cells. Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.711894
|
| 32 |
Ji Won Han, Ji Hoon Kim, Dong Hyun Kim, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jaegyoon Ahn, Hyun Yang, Pil Soo Sung. Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma. Diagnostics 2023; 13(8): 1453 doi: 10.3390/diagnostics13081453
|
| 33 |
Maria Tampaki, George V. Papatheodoridis, Evangelos Cholongitas. Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview. Cancers 2023; 15(4): 1310 doi: 10.3390/cancers15041310
|
| 34 |
Sarah Berhane, Richard Fox, Marta García-Fiñana, Alessandro Cucchetti, Philip Johnson. Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment. British Journal of Cancer 2019; 121(2): 117 doi: 10.1038/s41416-019-0488-4
|
| 35 |
Narayan Shivapurkar, Martha D. Gay, Aiwu (Ruth) He, Wenqiang Chen, Shermineh Golnazar, Hong Cao, Tetyana Duka, Bhaskar Kallakury, Sona Vasudevan, Jill P. Smith. Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. International Journal of Molecular Sciences 2023; 24(4): 3625 doi: 10.3390/ijms24043625
|
| 36 |
Lun Wu, Jiao Zhou, Wenbo Zhou, Xue-Fei Huang, Qinhua Chen, Wei Wang, Lulu Zhai, Shengwei Li, Zhigang Tang. Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo. Pathology - Research and Practice 2021; 220: 153270 doi: 10.1016/j.prp.2020.153270
|
| 37 |
Andrea Casadei-Gardini, Orsi Giulia, Caputo Francesco, Ercolani Giorgio. Developments in predictive biomarkers for hepatocellular carcinoma therapy. Expert Review of Anticancer Therapy 2020; 20(1): 63 doi: 10.1080/14737140.2020.1712198
|
| 38 |
Ya-Ting Yang, Vilma Yuzbasiyan-Gurkan. Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines. International Journal of Molecular Sciences 2022; 23(16): 9345 doi: 10.3390/ijms23169345
|
| 39 |
Xianli Tong, Qun Wang, Dongde Wu, Lequn Bao, Tao Yin, Hu Chen. MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo. Biochemical and Biophysical Research Communications 2020; 523(1): 147 doi: 10.1016/j.bbrc.2019.12.032
|
| 40 |
Lei Gong, Wenzhen Wang, Fei Yu, Zenghua Deng, Nan Luo, Xinjing Zhang, Jianfen Chen, Jirun Peng. Caffeic acid phenethyl ester derivative exerts remarkable anti-hepatocellular carcinoma effect, non-inferior to sorafenib, in vivo analysis. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-65496-1
|
| 41 |
Senbang Yao, Wenjun Chen, Tingting Chen, He Zuo, Ziran Bi, Xiuqing Zhang, Lulian Pang, Yanyan Jing, Xiangxiang Yin, Huaidong Cheng. A comprehensive computational analysis to explore the importance of SIGLECs in HCC biology. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02672-z
|
| 42 |
Zu‐Yau Lin, Ming‐Lun Yeh, Ching‐I Huang, Shinn‐Cherng Chen, Chung‐Feng Huang, Jee‐Fu Huang, Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang. Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression. The Kaohsiung Journal of Medical Sciences 2022; 38(2): 157 doi: 10.1002/kjm2.12471
|
| 43 |
Joji Nakayama, Zhiyuan Gong. Transgenic zebrafish for modeling hepatocellular carcinoma. MedComm 2020; 1(2): 140 doi: 10.1002/mco2.29
|
| 44 |
Haris Muhammad, Aniqa Tehreem, Peng-Sheng Ting, Merve Gurakar, Sean Young Li, Cem Simsek, Saleh A. Alqahtani, Amy K. Kim, Ruhail Kohli, Ahmet Gurakar. Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. Journal of Clinical and Translational Hepatology 2021; 0(000): 000 doi: 10.14218/JCTH.2021.00125
|
| 45 |
Elena De Mattia, Erika Cecchin, Michela Guardascione, Luisa Foltran, Tania Di Raimo, Francesco Angelini, Mario D’Andrea, Giuseppe Toffoli. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World Journal of Gastroenterology 2019; 25(29): 3870-3896 doi: 10.3748/wjg.v25.i29.3870
|
| 46 |
Raj M. Desai, Neha Desai, Munira Momin, Lokesh Kumar Bhatt. Sorafenib Loaded Resealed Erythrocytes for the Treatment of Hepatocellular
Carcinoma. Recent Advances in Drug Delivery and Formulation 2023; 17(1): 61 doi: 10.2174/2667387817666230228145946
|
| 47 |
David Dahlgren, Hans Lennernäs. Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective. Molecules 2020; 25(12): 2861 doi: 10.3390/molecules25122861
|
| 48 |
Anusha Sebastian, Reinad R. Abu Rabah, Seyed-Omar Zaraei, Srinivasulu Vunnam, Shaista Sultan, Hanan S. Anbar, Randa El-Gamal, Hamadeh Tarazi, Nadin Sarg, Dima W. Alhamad, Salma A. Al Shamma, Afnan I. Shahin, Hany A. Omar, Taleb H. Al-Tel, Mohammed I. El-Gamal. Design, synthesis, biological evaluation, and in silico studies of novel pyridopyridine derivatives as anticancer candidates targeting FMS kinase. European Journal of Medicinal Chemistry 2024; 274: 116557 doi: 10.1016/j.ejmech.2024.116557
|
| 49 |
Daniel Q. Huang, Mark D. Muthiah, Lei Zhou, Halisah Jumat, Wan Xin Tan, Guan Huei Lee, Seng Gee Lim, Alfred Kow, Glenn Bonney, Iyer Shridhar, Yi Ting Lim, Aileen Wee, Yin Huei Pang, Gwyneth Soon, Pierce Chow, Yock Young Dan. Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy. Cellular and Molecular Gastroenterology and Hepatology 2021; 11(5): 1313 doi: 10.1016/j.jcmgh.2020.12.009
|
| 50 |
Shukui Qin, Feng Bi, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Chengxu Cui, Bo Zhu, Jian Wu, Xiaoli Xin, Jufeng Wang, Jinlu Shan, Junhui Chen, Zhendong Zheng, Li Xu, Xiaoyu Wen, Zhenyu You, Zhenggang Ren, Xiufeng Liu, Meng Qiu, Liqing Wu, Feng Chen. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. Journal of Clinical Oncology 2021; 39(27): 3002 doi: 10.1200/JCO.21.00163
|
| 51 |
Leyi Yao, Ding Yan, Baoyi Jiang, Qian Xue, Xi Chen, Qingtian Huang, Ling Qi, Daolin Tang, Xin Chen, Jinbao Liu. Plumbagin is a novel GPX4 protein degrader that induces apoptosis in hepatocellular carcinoma cells. Free Radical Biology and Medicine 2023; 203: 1 doi: 10.1016/j.freeradbiomed.2023.03.263
|
| 52 |
Basma Hossam Abdelmonem, Noha M. Abdelaal, Eman K. E. Anwer, Alaa A. Rashwan, Mohamed Ali Hussein, Yasmin F. Ahmed, Rana Khashana, Mireille M. Hanna, Anwar Abdelnaser. Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review. Biomedicines 2024; 12(7): 1467 doi: 10.3390/biomedicines12071467
|
| 53 |
Francesca Matilde Schipilliti, Ingrid Garajová, Giulia Rovesti, Rita Balsano, Federico Piacentini, Massimo Dominici, Fabio Gelsomino. The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. Pharmaceuticals 2021; 14(1): 43 doi: 10.3390/ph14010043
|
| 54 |
Lydia Giannitrapani, Francesca Di Gaudio, Melchiorre Cervello, Francesca Scionti, Domenico Ciliberto, Nicoletta Staropoli, Giuseppe Agapito, Mario Cannataro, Pierfrancesco Tassone, Pierosandro Tagliaferri, Aurelio Seidita, Maurizio Soresi, Marco Affronti, Gaetano Bertino, Maurizio Russello, Rosaria Ciriminna, Claudia Lino, Francesca Spinnato, Francesco Verderame, Giuseppa Augello, Mariamena Arbitrio. Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences 2024; 25(4): 2197 doi: 10.3390/ijms25042197
|
| 55 |
Yue Wang, Tianli Chen, Kangshuai Li, Wentao Mu, Zengli Liu, Anda Shi, Jialiang Liu, Wei Zhao, Shuo Lian, Shaohui Huang, Chang Pan, Zongli Zhang. Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.777617
|
| 56 |
Jing Ni, Xianzhong Cheng, Rui Zhou, Qian Zhao, Xia Xu, Wenwen Guo, Hongyuan Gu, Chen Chen, Xiaoxiang Chen. Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.724620
|
| 57 |
Angélica Richart Csipak, Leonardo G. da Fonseca, Rossana Verónica Mendoza López, Maria Del Pilar Estevez-Diz. Real-World, Observational, Retrospective Study to Evaluate the Effectiveness and Safety of Treatment with Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Current Oncology 2024; 31(11): 6778 doi: 10.3390/curroncol31110500
|
| 58 |
Jinhu Wang, Wang Liu, Jean C. Li, Mingyi Li, Benyi Li, Runzhi Zhu. Hepcidin Downregulation Correlates With Disease Aggressiveness And Immune Infiltration in Liver Cancers. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.714756
|
| 59 |
Noe Rico Montanari, Chimaobi M. Anugwom, Andre Boonstra, Jose D. Debes. The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma. Cancers 2021; 13(19): 4876 doi: 10.3390/cancers13194876
|
| 60 |
Xianghong Lai, Anmei Wang, Dong Chen. Effects of Fufang Banmao Capsule Associated with Sorafenib on Liver Function, Immune Status, Quality of Life Improvement, and Survival in Patients with Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study. Computational Intelligence and Neuroscience 2022; 2022: 1 doi: 10.1155/2022/6336107
|
| 61 |
Wei Mu, Yaoli Xie, Jinhu Li, Runzhi Yan, Jingxian Zhang, Yu’e Liu, Yimin Fan. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma. World Journal of Surgical Oncology 2022; 20(1) doi: 10.1186/s12957-021-02479-w
|
| 62 |
Giovanni Marasco, Francesco Poggioli, Antonio Colecchia, Giuseppe Cabibbo, Filippo Pelizzaro, Edoardo Giannini, Sara Marinelli, Gian Rapaccini, Eugenio Caturelli, Mariella Di Marco, Elisabetta Biasini, Fabio Marra, Filomena Morisco, Francesco Foschi, Marco Zoli, Antonio Gasbarrini, Gianluca Svegliati Baroni, Alberto Masotto, Rodolfo Sacco, Giovanni Raimondo, Francesco Azzaroli, Andrea Mega, Gianpaolo Vidili, Maurizia Brunetto, Gerardo Nardone, Luigina Alemanni, Elton Dajti, Federico Ravaioli, Davide Festi, Franco Trevisani. A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. Cancers 2021; 13(11): 2677 doi: 10.3390/cancers13112677
|
| 63 |
Margherita Rimini, Shigeo Shimose, Sara Lonardi, Toshifumi Tada, Gianluca Masi, Hideki Iwamoto, Eleonora Lai, Valentina Burgio, Atsushi Hiraoka, Toru Ishikawa, Caterina Soldà, Tomotake Shirono, Caterina Vivaldi, Koichi Takaguchi, Noritomo Shimada, Giorgio Astara, Hironori Koga, Kazuhiro Nouso, Kouji Joko, Takuji Torimura, Yoichi Hiasa, Francesca Salani, Mario Scartozzi, Stefano Cascinu, Andrea Casadei‐Gardini. Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study. Hepatology Research 2021; 51(12): 1229 doi: 10.1111/hepr.13718
|
| 64 |
Clelia Donisi, Marco Puzzoni, Pina Ziranu, Eleonora Lai, Stefano Mariani, Giorgio Saba, Valentino Impera, Marco Dubois, Mara Persano, Marco Migliari, Andrea Pretta, Nicole Liscia, Giorgio Astara, Mario Scartozzi. Immune Checkpoint Inhibitors in the Treatment of HCC. Frontiers in Oncology 2021; 10 doi: 10.3389/fonc.2020.601240
|
| 65 |
Xiaomin Zhang, Fu’an Wang, Guangfeng Gu, Qingpo Wu, Nicola Silvestris. High HBV Load Weakens Predictive Effect of Serum miR-122 on Response to Sorafenib in Hepatocellular Carcinoma Patients. Journal of Oncology 2021; 2021: 1 doi: 10.1155/2021/9938207
|
| 66 |
Jana Nekvindova, Alena Mrkvicova, Veronika Zubanova, Alena Hyrslova Vaculova, Pavel Anzenbacher, Pavel Soucek, Lenka Radova, Ondrej Slaby, Igor Kiss, Jan Vondracek, Alena Spicakova, Lucia Bohovicova, Pavel Fabian, Zdenek Kala, Vladimir Palicka. Hepatocellular carcinoma: Gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450. Biochemical Pharmacology 2020; 177: 113912 doi: 10.1016/j.bcp.2020.113912
|
| 67 |
Ulkuhan Iner Koksal, Sezer Saglam, Murat Dayangac, Gulen Bulbul Dogusoy, Murat Akyildiz, Murat Buyukdogan, Egzona Qipa. The Prognostic Role of VEGFR-2 Gene Amplification in Relation to Serum AFP Levels Among Liver-Transplanted Patients with Hepatocellular Carcinoma. Journal of Current Oncology 2022; 5(2): 85 doi: 10.1177/25898892221145210
|
| 68 |
Deyao Zhang, Lanqing Huo, Yangxun Pan, Zhenyun Yang, Huilan Zeng, Xin Wang, Jinbin Chen, Juncheng Wang, Yaojun Zhang, Zhongguo Zhou, Minshan Chen, Dandan Hu. A Systemic Inflammation Response Score for Prognostic Prediction in Hepatocellular Carcinoma Patients After Hepatectomy. Journal of Inflammation Research 2022; : 6869 doi: 10.2147/JIR.S397375
|
| 69 |
Mustafa Nazzal, Subhayan Sur, Robert Steele, Mousumi Khatun, Tapas Patra, Nancy Phillips, John Long, Ranjit Ray, Ratna B. Ray. Establishment of a Patient‐Derived Xenograft Tumor From Hepatitis C–Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy. Hepatology 2020; 72(2): 379 doi: 10.1002/hep.31298
|
| 70 |
Rania Harati, Marc Vandamme, Benoit Blanchet, Christophe Bardin, Françoise Praz, Rifat Akram Hamoudi, Christèle Desbois-Mouthon. Drug-Drug Interaction between Metformin and Sorafenib Alters Antitumor Effect in Hepatocellular Carcinoma Cells. Molecular Pharmacology 2021; 100(1): 32 doi: 10.1124/molpharm.120.000223
|
| 71 |
Pusen Wang, Zhongyi Jiang, Xueni Liu, Kanru Yu, Chunguang Wang, Hao Li, Lin Zhong. PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma. Cancer Medicine 2020; 9(19): 6972 doi: 10.1002/cam4.3331
|
| 72 |
Luca Faloppi, Marco Puzzoni, Andrea Casadei Gardini, Nicola Silvestris, Gianluca Masi, Giorgia Marisi, Caterina Vivaldi, Cosmo Damiano Gadaleta, Pina Ziranu, Maristella Bianconi, Cristian Loretelli, Laura Demurtas, Eleonora Lai, Riccardo Giampieri, Eva Galizia, Paola Ulivi, Nicola Battelli, Alfredo Falcone, Stefano Cascinu, Mario Scartozzi. Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. Targeted Oncology 2020; 15(1): 115 doi: 10.1007/s11523-020-00698-x
|
| 73 |
Polina Suter, Eva Dazert, Jack Kuipers, Charlotte K. Y. Ng, Tuyana Boldanova, Michael N. Hall, Markus H. Heim, Niko Beerenwinkel, Carl Herrmann. Multi-omics subtyping of hepatocellular carcinoma patients using a Bayesian network mixture model. PLOS Computational Biology 2022; 18(9): e1009767 doi: 10.1371/journal.pcbi.1009767
|
| 74 |
Wei Yuan, Wenchao Yue, Huabing Wen, Xueqin Wang, Qi Wang. Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or without Lenvatinib for Unresectable Hepatocellular Carcinoma. European Surgical Research 2023; 64(2): 268 doi: 10.1159/000529475
|
| 75 |
Zhiwei Shao, Haoqi Pan, Sheng Tu, Jingying Zhang, Sheng Yan, Anwen Shao. HGF/c-Met Axis: The Advanced Development in Digestive System Cancer. Frontiers in Cell and Developmental Biology 2020; 8 doi: 10.3389/fcell.2020.00801
|
| 76 |
Luai Madanat, Ruby Gupta, Paul Weber, Navneet Kumar, Rohit Chandra, Hycienth Ahaneku, Yatharth Bansal, Joseph Anderson, Abhay Bilolikar, Ishmael Jaiyesimi. Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth
Review. Current Cardiology Reviews 2023; 19(3) doi: 10.2174/1573403X18666220531094800
|
| 77 |
Xuebing Jia, Lei Li, Fan Wang, Ying Xue, Tongde Wu, Qianqian Jia, Yunhui Li, Chenming Wu, Yuping Chen, Jinhuan Wu, Yang Su, Xinshu Wang, Tao Zhuang, Xiao Dong, Jing Ling, Jian Yuan, Qi Li. DUB3/KLF4 combats tumor growth and chemoresistance in hepatocellular carcinoma. Cell Death Discovery 2022; 8(1) doi: 10.1038/s41420-022-00988-5
|
| 78 |
Tim A. Labeur, Sarah Berhane, Julien Edeline, Jean‐Frederic Blanc, Dominik Bettinger, Tim Meyer, Jeroen L. A. Van Vugt, David W. G. Ten Cate, Robert A. De Man, Ferry A. L. M. Eskens, Alessandro Cucchetti, Laura J. Bonnett, Otto M. Van Delden, Heinz‐Josef Klümpen, R. Bart Takkenberg, Philip J. Johnson. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib. Liver International 2020; 40(1): 215 doi: 10.1111/liv.14270
|
| 79 |
Qingli Li, Tianqiang Song. Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.633033
|
| 80 |
Doaa S. R. Khafaga, M. M. Eid, Mona H. Mohamed, Mohamed D. E. Abdelmaksoud, Mie Afify, Ahmed M. El-Khawaga, Heba K. Abdelhakim. Enhanced anticancer activity of silver doped zinc oxide magnetic nanocarrier loaded with sorafenib for hepatocellular carcinoma treatment. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-65235-6
|
| 81 |
Jie Zhang, Jingfei Zhao, Shuichun Wei, Peipei Huang, Xinyue Tu, Guimin Su, Yu Gan, Wenfeng Gong, Bangde Xiang. Developing and Validating an Autophagy Gene-Set-Based Prognostic Signature in Hepatocellular Carcinoma Patients. International Journal of General Medicine 2022; : 8399 doi: 10.2147/IJGM.S388592
|
| 82 |
Pramodkumar Pyarelal Gupta, Viraj Jitendra Sadrani, Priyanshu Pramodkumar Gupta, Mala Makarand Parab, Virupaksha Ajit Bastikar. Oncogenic Viruses. 2023; : 243 doi: 10.1016/B978-0-12-824152-3.00003-2
|
| 83 |
Giuseppe Corrias, Eleonora Lai, Pina Ziranu, Stefano Mariani, Clelia Donisi, Nicole Liscia, Giorgio Saba, Andrea Pretta, Mara Persano, Daniela Fanni, Dario Spanu, Francesca Balconi, Francesco Loi, Simona Deidda, Angelo Restivo, Valeria Pusceddu, Marco Puzzoni, Cinzia Solinas, Elena Massa, Clelia Madeddu, Clara Gerosa, Luigi Zorcolo, Gavino Faa, Luca Saba, Mario Scartozzi. Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging. Cancers 2024; 16(7): 1364 doi: 10.3390/cancers16071364
|
| 84 |
Ling Wei, Yongzhi Lun, Xiaoping Zhou, Shang He, Lijuan Gao, Yan Liu, Zheng He, Baoming Li, Chengbin Wang. Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo. Pharmacological Research 2019; 143: 73 doi: 10.1016/j.phrs.2019.03.009
|
| 85 |
Merin Babu, Shine Sadasivan, Aneesh T P, Teun Van Gelder, Shiny Thomas, C T Aravindkumar, Niveditha Kartha, Keechilat Pavithran. Therapeutic Drug Monitoring of Sorafenib and Lenvatinib in Hepatocellular Carcinoma Patients – A Key to Personalised Pharmacotherapy. F1000Research 2024; 13: 1334 doi: 10.12688/f1000research.153153.1
|
| 86 |
C. Ventura, M. Junco, F.X. Santiago Valtierra, M. Gooz, Y. Zhiwei, D.M. Townsend, P.M. Woster, E.N. Maldonado. Synergism of small molecules targeting VDAC with sorafenib, regorafenib or lenvatinib on hepatocarcinoma cell proliferation and survival. European Journal of Pharmacology 2023; 957: 176034 doi: 10.1016/j.ejphar.2023.176034
|
| 87 |
Tim A. Labeur, Quincy Hofsink, R. Bart Takkenberg, Otto M. van Delden, Ron A. A. Mathôt, Regina Schinner, Peter Malfertheiner, Holger Amthauer, Kerstin Schütte, Bristi Basu, Christiane Kuhl, Julia Mayerle, Jens Ricke, Heinz-Josef Klümpen. The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma – a substudy of the SORAMIC trial. Acta Oncologica 2020; 59(9): 1028 doi: 10.1080/0284186X.2020.1759826
|
| 88 |
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Federico Rossari, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Francesca Bergamo, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo Alberto Iavarone, Giuseppe Cabibbo, Margarida Montes, Francesco Giuseppe Foschi, Caterina Vivaldi, Caterina Soldà, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Mariangela Bruccoleri, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Silvia Foti, Silvia Camera, Fabio Piscaglia, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab. Targeted Oncology 2024; 19(4): 645 doi: 10.1007/s11523-024-01061-0
|
| 89 |
Sang Bae Lee, KyeongJin Kim. Correspondence to editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”. Clinical and Molecular Hepatology 2025; 31(1): e78 doi: 10.3350/cmh.2024.0750
|
| 90 |
Yan Li, Tianyu Tang, Hae June Lee, Kiwon Song. Selective Anti-Cancer Effects of Plasma-Activated Medium and Its High Efficacy with Cisplatin on Hepatocellular Carcinoma with Cancer Stem Cell Characteristics. International Journal of Molecular Sciences 2021; 22(8): 3956 doi: 10.3390/ijms22083956
|
| 91 |
Alice Boilève, Cristina Smolenschi, Alina Fuerea, Antoine Hollebecque, Valérie Boige. Metastatic hepatocellular carcinoma cured by exclusive systemic antiangiogenic therapy: Two cases along with tumor molecular profiles. Digestive and Liver Disease 2021; 53(8): 1059 doi: 10.1016/j.dld.2021.04.033
|
| 92 |
Weiwei Ke, Hongbo Wang, Xiangxuan Zhao, Zaiming Lu. Foeniculum vulgare seed extract exerts anti-cancer effects on hepatocellular carcinoma. Food & Function 2021; 12(4): 1482 doi: 10.1039/D0FO02243H
|
| 93 |
Jun Hou, Changqing Jiang, Xudong Wen, Chengming Li, Shiqiang Xiong, Tian Yue, Pan Long, Jianyou Shi, Zhen Zhang. ACSL4 as a Potential Target and Biomarker for Anticancer: From Molecular Mechanisms to Clinical Therapeutics. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.949863
|
| 94 |
Maciej Gryziak, Krzysztof Woźniak, Leszek Kraj, Rafał Stec. Milestones in the treatment of hepatocellular carcinoma: A systematic review.. Critical Reviews in Oncology/Hematology 2021; 157: 103179 doi: 10.1016/j.critrevonc.2020.103179
|
| 95 |
Kirti Agrawal, Saniya Arfin, Manish K. Mishra, Sitaram Harihar, Kavindra Kumar Kesari, Shubhadeep Roychoudhury, Dhruv Kumar. Autophagy and Metabolism. 2022; : 119 doi: 10.1016/B978-0-323-99879-6.00013-4
|
| 96 |
Ji Kim, Young Kim, Hee-Chul Nam, Chang-Wook Kim, Jae-Sung Yoo, Ji Han, Jeong Jang, Jong Choi, Seung Yoon, Ho Jong Chun, Jung Oh, Suho Kim, Sung Lee, Pil Sung. Consistent efficacy of hepatic artery infusion chemotherapy irrespective of PD‑L1 positivity in unresectable hepatocellular carcinoma. Oncology Letters 2024; 28(2) doi: 10.3892/ol.2024.14521
|
| 97 |
Rakesh Kapoor, Treshita Dey, Divya Khosla, Sunil Taneja, Naveen Kalra, Rajesh Gupta. Bridging hope: Retrospective analysis of stereotactic radiotherapy in patients with hepatocellular carcinoma-A promising and cost-effective solution for low-and middle-income countries. Cancer Research, Statistics, and Treatment 2024; 7(3): 326 doi: 10.4103/crst.crst_413_23
|
| 98 |
Andrea Casadei-Gardini, Leonardo Solaini, Laura Riggi, Eleonora Molinaro, Vincenzo Dadduzio, Mario Domenico Rizzato, Antonio Pellino, Luca Faloppi, Giorgia Marisi, Paola Ulivi, Matteo Canale, Giulia Orsi, Giulia Rovesti, Kalliopi Andrikou, Andrea Spallanzani, Fabio Gelsomino, Francesco Giuseppe Foschi, Fabio Conti, Alessandro Cucchetti, Giorgio Ercolani, Paola Biason, Sara Lonardi, Stefano Cascinu, Mario Scartozzi. Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. Gastrointestinal Tumors 2019; 6(3-4): 71 doi: 10.1159/000501593
|
| 99 |
Hiroyuki Suzuki, Hideki Iwamoto, Takashi Niizeki, Shigeo Shimose, Tomotake Shirono, Taizo Yamaguchi, Hirohisa Yano, Yasuji Okuda, Hironori Koga, Takuji Torimura. A long-term survival case of advanced hepatocellular carcinoma treated with multidisciplinary therapies with progression to hepatic arterial infusion chemotherapy and hepatectomy. Kanzo 2020; 61(8): 418 doi: 10.2957/kanzo.61.418
|
| 100 |
Anita Bakrania, Gang Zheng, Mamatha Bhat. Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics 2021; 14(1): 41 doi: 10.3390/pharmaceutics14010041
|
| 101 |
Andrea Casadei-Gardini, Giorgia Marisi, Vincenzo Dadduzio, Laura Gramantieri, Luca Faloppi, Paola Ulivi, Francesco Giuseppe Foschi, Emiliano Tamburini, Caterina Vivaldi, Mario Domenico Rizzato, Luca Ielasi, Matteo Canale, Fabio Conti, Britt Rudnas, Lorenzo Fornaro, Nicola Silvestris, Marianna Silletta, Giovanni Gerardo Cardellino, Sara Lonardi, Francesca Fornari, Giulia Orsi, Giulia Rovesti, Vittorina Zagonel, Stefano Cascinu, Mario Scartozzi. Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. Clinical Cancer Research 2020; 26(17): 4485 doi: 10.1158/1078-0432.CCR-19-3897
|
| 102 |
Giorgia Marisi, Elisabetta Petracci, Francesco Raimondi, Luca Faloppi, Francesco Giuseppe Foschi, Gianfranco Lauletta, Massimo Iavarone, Matteo Canale, Martina Valgiusti, Luca Maria Neri, Paola Ulivi, Giulia Orsi, Giulia Rovesti, Ranka Vukotic, Fabio Conti, Alessandro Cucchetti, Giorgio Ercolani, Kalliopi Andrikou, Stefano Cascinu, Mario Scartozzi, Andrea Casadei-Gardini. ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. Cancers 2019; 11(7): 1023 doi: 10.3390/cancers11071023
|
| 103 |
Fatemeh Abbaszadeh, Sajad Fakhri, Sana Piri, Haroon Khan. Phytonutrients in the Treatment of Gastrointestinal Cancer. 2023; : 1 doi: 10.2174/9789815049633123010004
|
| 104 |
Zaiba Shafik Dawood, Zachary J. Brown, Yutaka Endo, Erryk S. Katayama, Muhammad Musaab Munir, Laura Alaimo, Samantha M. Ruff, Henrique A. Lima, Selamawit Woldesenbet, Timothy M. Pawlik. Cost effectiveness of immune checkpoint inhibitors for treatment of Hepatocellular Carcinoma: A systematic review and Meta-analysis. Surgical Oncology 2023; 51: 102013 doi: 10.1016/j.suronc.2023.102013
|
| 105 |
Shuping Zhou, Yongfang Ma, Ruyue Xu, Xiaolong Tang. Nanoparticles Loaded with GSK1059615 Combined with Sorafenib Inhibited Programmed Cell Death 1 Ligand 1 Expression by Negatively Regulating the PI3K/Akt/NF-κB Pathway, Thereby Reversing the Drug Resistance of Hepatocellular Carcinoma to Sorafenib. Journal of Biomedical Nanotechnology 2022; 18(3): 693 doi: 10.1166/jbn.2022.3279
|
| 106 |
Jingyao Cai, Min Hu, Zhiyang Chen, Zeng Ling. The roles and mechanisms of hypoxia in liver fibrosis. Journal of Translational Medicine 2021; 19(1) doi: 10.1186/s12967-021-02854-x
|
| 107 |
María Hernández‑bule, María Martínez, María Trillo, Lidia Martínez, Elena Toledano‑Macías, Alejandro Úbeda. Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current. Oncology Letters 2021; 22(5) doi: 10.3892/ol.2021.13068
|
| 108 |
Wu Jing, Liu Shuo, Xing Yingru, Mu Min, Zhao Runpeng, Xie Jun, Hu Dong. Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma. Biochemical and Biophysical Research Communications 2019; 519(1): 41 doi: 10.1016/j.bbrc.2019.08.115
|
| 109 |
Neehar D Parikh, Alexander Marshall, Keith A Betts, Jinlin Song, Jing Zhao, Muhan Yuan, Aozhou Wu, Keith D Huff, Richard Kim. Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. Journal of Comparative Effectiveness Research 2021; 10(5): 343 doi: 10.2217/cer-2020-0236
|
| 110 |
Satoshi Noda, Daiki Hira, Rie Osaki, Takehide Fujimoto, Hiroya Iida, Sachiko Tanaka-Mizuno, Akira Andoh, Masaji Tani, Yoshito Ikeda, Shin-ya Morita, Tomohiro Terada. Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study. Cancer Chemotherapy and Pharmacology 2020; 86(1): 129 doi: 10.1007/s00280-020-04105-0
|
| 111 |
Giovanni Marasco, Antonio Colecchia, Maria Letizia Bacchi Reggiani, Ciro Celsa, Fabio Farinati, Edoardo Giovanni Giannini, Francesca Benevento, Gian Ludovico Rapaccini, Eugenio Caturelli, Mariella Di Marco, Elisabetta Biasini, Fabio Marra, Filomena Morisco, Francesco Giuseppe Foschi, Marco Zoli, Antonio Gasbarrini, Gianluca Svegliati Baroni, Alberto Masotto, Rodolfo Sacco, Giovanni Raimondo, Francesco Azzaroli, Andrea Mega, Gianpaolo Vidili, Maurizia Rossana Brunetto, Gerardo Nardone, Elton Dajti, Federico Ravaioli, Francesca Avanzato, Davide Festi, Franco Trevisani. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.. Digestive and Liver Disease 2021; 53(8): 1011 doi: 10.1016/j.dld.2020.12.001
|
| 112 |
Laura Marconato, Silvia Sabattini, Giorgia Marisi, Federica Rossi, Vito Ferdinando Leone, Andrea Casadei-Gardini. Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs. Cancers 2020; 12(5): 1272 doi: 10.3390/cancers12051272
|
| 113 |
Reinad R. Abu Rabah, Anusha Sebastian, Srinivasulu Vunnam, Shaista Sultan, Hamadeh Tarazi, Hanan S. Anbar, Mahmoud K. Shehata, Seyed-Omar Zaraei, Sara M. Elgendy, Salma A. Al Shamma, Hany A. Omar, Taleb H. Al-Tel, Mohammed I. El-Gamal. Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors. Bioorganic & Medicinal Chemistry 2022; 69: 116894 doi: 10.1016/j.bmc.2022.116894
|
| 114 |
Iason Psilopatis, Christos Damaskos, Anna Garmpi, Panagiotis Sarantis, Evangelos Koustas, Efstathios A. Antoniou, Dimitrios Dimitroulis, Gregory Kouraklis, Michail V. Karamouzis, Kleio Vrettou, Georgios Marinos, Konstantinos Kontzoglou, Nikolaos Garmpis. FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?. International Journal of Molecular Sciences 2023; 24(3): 2685 doi: 10.3390/ijms24032685
|
| 115 |
Mario Frías, Antonio Rivero-Juárez, Isabel Machuca, Ángela Camacho, Antonio Rivero. The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. Expert Review of Precision Medicine and Drug Development 2020; 5(4): 253 doi: 10.1080/23808993.2020.1764346
|
| 116 |
Je-Ming Hu, Yung-Lung Chang, Cheng-Chih Hsieh, Shih-Ming Huang. The Synergistic Cytotoxic Effects of GW5074 and Sorafenib by Impacting Mitochondrial Functions in Human Colorectal Cancer Cell Lines. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.925653
|
| 117 |
Aini Hyytiäinen, Wafa Wahbi, Otto Väyrynen, Kauko Saarilahti, Peeter Karihtala, Tuula Salo, Ahmed Al-Samadi. Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.683570
|
| 118 |
Alina-Veronica Ghionescu, Andrei Sorop, Simona Olimpia Dima. The pivotal role of EMT-related noncoding RNAs regulatory axes in hepatocellular carcinoma. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1270425
|
| 119 |
Xueyan Sun, Zhizhong Xie, Xiaoyong Lei, Sheng Huang, Guotao Tang, Zhe Wang. Research and development ofN,N′-diarylureas as anti-tumor agents. RSC Medicinal Chemistry 2023; 14(7): 1209 doi: 10.1039/D3MD00053B
|
| 120 |
Bart Vanderborght, Sander Lefere, Hans Van Vlierberghe, Lindsey Devisscher. The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma. Cells 2020; 9(11): 2382 doi: 10.3390/cells9112382
|
| 121 |
Zhidong Fu, Lihui Jiang. Chebulinic Acid Ameliorates Diethylnitrosamine-Induced Hepatocarcinogenesis in Rats by Inhibiting AKT/mTOR Activation and Inhibits Liver Cancer Cell (HepG2) Proliferation. Revista Brasileira de Farmacognosia 2024; 35(1): 101 doi: 10.1007/s43450-024-00590-z
|
| 122 |
Chang Min Kim, Shin Hwang, Bhumsuk Keam, Yun Suk Yu, Ji Hoon Kim, Dong-Sik Kim, Si Hyun Bae, Gun-Do Kim, Jong Kyu Lee, Yong Bae Seo, Soon Woo Nam, Koo Jeong Kang, Luigi Buonaguro, Jin Young Park, Yun Soo Kim, Hee Jung Wang. Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker. Liver Cancer 2020; 9(2): 182 doi: 10.1159/000504548
|
| 123 |
Andrea Casadei‐Gardini, Giuseppe Cabibbo, Vincenzo Dadduzio, Giulia Orsi, Ranka Vukotic, Mario Domenico Rizzato, Margherita Rossi, Valeria Guarneri, Sara Lonardi, Dario D'Agostino, Ciro Celsa, Giulia Rovesti, Margherita Rimini, Pietro Andreone, Vittorina Zagonel, Mario Scartozzi, Philip Johnson, Stefano Cascinu, Alessandro Cucchetti. Validation and refinement of PROSASH model using the neutrophil‐to‐lymphocyte ratio in patients with HCC receiving sorafenib. Liver Cancer International 2020; 1(1): 6 doi: 10.1002/lci2.12
|
| 124 |
Margherita Rimini, Changhoon Yoo, Sara Lonardi, Gianluca Masi, Alessandro Granito, Yeonghak Bang, Mario Domenico Rizzato, Caterina Vivaldi, Luca Ielasi, Hyung-Don Kim, Francesca Bergamo, Francesca Salani, Simona Leoni, Baek-Yeol Ryoo, Min-Hee Ryoo, Valentina Burgio, Stefano Cascinu, Andrea Casadei-Gardini. Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience. Targeted Oncology 2021; 16(5): 653 doi: 10.1007/s11523-021-00834-1
|
| 125 |
Rhys Gillman, Matt A. Field, Ulf Schmitz, Rozemary Karamatic, Lionel Hebbard. Identifying cancer driver genes in individual tumours. Computational and Structural Biotechnology Journal 2023; 21: 5028 doi: 10.1016/j.csbj.2023.10.019
|
| 126 |
Peter R Galle, Jean-François Dufour, Markus Peck-Radosavljevic, Jörg Trojan, Arndt Vogel. Systemic Therapy of Advanced Hepatocellular Carcinoma. Future Oncology 2021; 17(10): 1237 doi: 10.2217/fon-2020-0758
|
| 127 |
Peter R. Galle, Friedrich Foerster, Masatoshi Kudo, Stephen L. Chan, Josep M. Llovet, Shukui Qin, William R. Schelman, Sudhakar Chintharlapalli, Paolo B. Abada, Morris Sherman, Andrew X. Zhu. Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma. Liver International 2019; 39(12): 2214 doi: 10.1111/liv.14223
|
| 128 |
Vichununt Kerdput, Cheng Nilbu-nga, Nattpawit Kaewnoonual, Arunporn Itharat, Suriya Pongsawat, Wisuit Pradidarcheep. Therapeutic efficacy of a Dioscorea membranacea extract in a rat model of hepatocellular carcinoma: Histopathological aspects. Journal of Traditional and Complementary Medicine 2021; 11(5): 400 doi: 10.1016/j.jtcme.2021.02.001
|
| 129 |
Aman Opneja, Gino Cioffi, Asrar Alahmadi, Nelroy Jones, Tin‐Yun Tang, Nirav Patil, David L. Bajor, Joel N. Saltzman, Amr Mohamed, Eva Selfridge, Ankit Mangla, Jill Barnholtz‐Sloan, Richard T. Lee. Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004–2014. Cancer Medicine 2021; 10(13): 4397 doi: 10.1002/cam4.3985
|
| 130 |
Giulia Rovesti, Giulia Orsi, Andrikou Kalliopi, Caterina Vivaldi, Giorgia Marisi, Luca Faloppi, Francesco Giuseppe Foschi, Nicola Silvestris, Irene Pecora, Giuseppe Aprile, Eleonora Molinaro, Laura Riggi, Paola Ulivi, Matteo Canale, Alessandro Cucchetti, Emiliano Tamburini, Giorgio Ercolani, Lorenzo Fornaro, Pietro Andreone, Patrizia Zavattari, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini. Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. Gastrointestinal Tumors 2019; 6(3-4): 92 doi: 10.1159/000502714
|
| 131 |
Ji Feng, Pei-zhi Lu, Guang-zhi Zhu, Shing Chung Hooi, Yong Wu, Xiao-wei Huang, Hui-qi Dai, Pan-hong Chen, Zhong-jie Li, Wen-jing Su, Chuang-ye Han, Xin-ping Ye, Tao Peng, Jing Zhou, Guo-dong Lu. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma. Acta Pharmacologica Sinica 2021; 42(1): 160 doi: 10.1038/s41401-020-0439-x
|
| 132 |
Aydin Eresen, Zigeng Zhang, Guangbo Yu, Qiaoming Hou, Zhilin Chen, Zeyang Yu, Vahid Yaghmai, Zhuoli Zhang. Sorafenib plus memory-like natural killer cell immunochemotherapy boosts treatment response in liver cancer. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-12718-4
|
| 133 |
Luzie A. Doemel, Julius Chapiro, Fabian Laage Gaupp, Lynn Jeanette Savic, Ahmet S. Kucukkaya, Alexandra Petukhova, Jonathan Tefera, Tal Zeevi, MingDe Lin, Todd Schlachter, Ariel Jaffe, Mario Strazzabosco, Timil Patel, Stacey M. Stein. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI. European Radiology 2021; 31(5): 2737 doi: 10.1007/s00330-020-07381-9
|
| 134 |
Monika Moser, Iuliana‐Pompilia Radu, Jean‐François Dufour. Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib. JGH Open 2021; 5(8): 864 doi: 10.1002/jgh3.12533
|
| 135 |
Asmaa M. El-Sheshtawy, Rehab H. Werida, Monir Hussein Bahgat, Shahira El-Etreby, Noha A. El-Bassiouny. Pharmacogenomic insights: IL-23R and ATG-10 polymorphisms in Sorafenib response for hepatocellular carcinoma. Clinical and Experimental Medicine 2025; 25(1) doi: 10.1007/s10238-025-01576-4
|
| 136 |
Tim A. Labeur, Sarah Berhane, Philip J. Johnson. Response to: Prognostication of HCC patients under sorafenib is not always possible. Liver International 2020; 40(5): 1243 doi: 10.1111/liv.14335
|
| 137 |
Francesco Caputo, Vincenzo Dadduzio, Francesco Tovoli, Giulia Bertolini, Giuseppe Cabibbo, Krisida Cerma, Caterina Vivaldi, Luca Faloppi, Mario Domenico Rizzato, Fabio Piscaglia, Ciro Celsa, Lorenzo Fornaro, Giorgia Marisi, Fabio Conti, Nicola Silvestris, Marianna Silletta, Sara Lonardi, Alessandro Granito, Caterina Stornello, Valentina Massa, Giorgio Astara, Sabina Delcuratolo, Stefano Cascinu, Mario Scartozzi, Andrea Casadei-Gardini, Matias A. Avila. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLOS ONE 2020; 15(5): e0232449 doi: 10.1371/journal.pone.0232449
|
| 138 |
Yu‑Xue Gao, Tong‑Wang Yang, Ji‑Ming Yin, Peng‑Xiang Yang, Bu‑Xin Kou, Meng‑Yin Chai, Xiao‑Ni Liu, De‑Xi Chen. Progress and prospects of biomarkers in�primary liver cancer (Review). International Journal of Oncology 2020; doi: 10.3892/ijo.2020.5035
|
| 139 |
Insija Ilyas Selene, Merve Ozen, Reema A. Patel. Hepatocellular Carcinoma: Advances in Systemic Therapy. Seminars in Interventional Radiology 2024; 41(01): 056 doi: 10.1055/s-0044-1779713
|
| 140 |
S. Gupta, A. Deb, P.B. Mazumder, G.S. Shekhawat. Exosomes as a window of opportunity in hepatocellular carcinoma: Insights from diagnostic to targeted drug delivery. Journal of Drug Delivery Science and Technology 2024; 101: 106259 doi: 10.1016/j.jddst.2024.106259
|
| 141 |
Junjie Hong, Xiujun Cai, Atif Ali Hashmi. Construction of a Novel Oxidative Stress Response-Related Gene Signature for Predicting the Prognosis and Therapeutic Responses in Hepatocellular Carcinoma. Disease Markers 2022; 2022: 1 doi: 10.1155/2022/6201987
|
| 142 |
Thomas M. Ruli, Ethan D. Pollack, Atul Lodh, Charles D. Evers, Christopher A. Price, Mohamed Shoreibah. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review. Cancers 2024; 16(11): 2042 doi: 10.3390/cancers16112042
|
| 143 |
Lei Li, Tao Wang, Shanbao Li, Zhengqian Chen, Junyi Wu, Wanyue Cao, Qi Wo, Xuebin Qin, Junming Xu. TDO2 Promotes the EMT of Hepatocellular Carcinoma Through Kyn-AhR Pathway. Frontiers in Oncology 2021; 10 doi: 10.3389/fonc.2020.562823
|
| 144 |
Andrea Casadei-Gardini, Vincenzo Dadduzio, Giulia Rovesti, Giuseppe Cabibbo, Ranka Vukotic, Mario Domenico Rizzato, Giulia Orsi, Margherita Rossi, Valeria Guarneri, Sara Lonardi, Dario D’agostino, Ciro Celsa, Pietro Andreone, Vittorina Zagonel, Mario Scartozzi, Stefano Cascinu, Alessandro Cucchetti. Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. Medicine 2020; 99(22): e19958 doi: 10.1097/MD.0000000000019958
|
| 145 |
Yu-Yun Shao, Pai-Sheng Chen, Liang-In Lin, Bin-Shyun Lee, Andrew Ling, Ann-Lii Cheng, Chiun Hsu, Da-Liang Ou. Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma. British Journal of Cancer 2022; 126(12): 1806 doi: 10.1038/s41416-022-01759-w
|
| 146 |
Adrian Kuzmanović, Cheng Lin, Matthias Bartneck. Hepatobiliary Cancers: An Interdisciplinary Approach. Interdisciplinary Cancer Research 2023; 3: 283 doi: 10.1007/16833_2023_129
|